

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1477)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT ENROLLED IN THE CLINICAL TRIAL OF
SELF-DEVELOPED CLASS I NEW DRUG OT-202 IN CHINA

This announcement is made by Ocumension Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the “**Board**”) of directors of the Company is pleased to announce that OT-202 (tyrosine kinase inhibitor), a class I new drug self-developed by the Company for the treatment of dry eye, has completed the first patient enrollment for its randomized, double-blind, placebo-controlled clinical trial on the safety, tolerability and pharmacokinetic properties for its single/multiple administration on healthy trial subjects in China.

OT-202 (tyrosine kinase inhibitor) is the Company’s first self-developed class I novel targeted new drug for the treatment of dry eye. The core mechanism of dry eye is mainly due to a variety of factors and diseases caused by the decrease in tear production or high evaporation, which leads to hypertonicity of tears. This hypertonic state activates by a series of inflammations on the ocular surface and releases inflammatory mediators into the tears fluid, and thus the cycle continues. The key treatment for dry eye is to break the vicious circle of inflammation. Spleen tyrosine kinase (Syk) is a cytoplasmic protein kinase, which plays a key role in a variety of biological functions, including classical immunoreceptor such as activating Fc receptors (FcR) and the intracellular signal cascade of B cells receptors (BCRs) that are particularly significant for the initiation of inflammation. Syk inhibitors can be used for the treatment of various allergic diseases, autoimmune diseases and inflammatory diseases. Syk is the target of OT-202, which achieves anti-inflammatory effects by inhibiting the activity of Syk kinase, which has shown significant therapeutic effects and anti-inflammatory effects in the guinea pigs’ immune-type dry eye model and the mice’s scopolamine dry eye model. The toxicology studies have also shown that it is well-tolerated in the body of animals.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-202 (tyrosine kinase inhibitor) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, January 4, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive directors.